SynthesisPloS one2017
Phosphatase and tensin homolog (PTEN) expression on oncologic outcome in renal cell carcinoma: A systematic review and meta-analysis.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.JCO precision oncology · 2022Trial
- [Expression of Rho-related BTB domain-containing protein 1 in tongue squamous cell carcinoma and its effect on cell proliferation, invasion, and migration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Cancer prognosis and treatment results in patients with PTEN Hamartoma Tumour Syndrome (PHTS)-a European cohort study.BJC reports · 2025Article
- Evaluation of the Expression of IDO and PTEN in Human Kidney Cancer.Current issues in molecular biology · 2025Article
- Expression and prognostic significance of microsomal triglyceride transfer protein in brain tumors: a retrospective cohort study.Translational cancer research · 2024Article
- Effect of Silibinin on the Expression of Mir-20b, Bcl2L11, and Erbb2 in Breast Cancer Cell Lines.Molecular biotechnology · 2023Article
- Pten knockout affects drug resistance differently in melanoma and kidney cancer.Pharmacological reports : PR · 2023Article
- Low gamma-butyrobetaine dioxygenase (BBOX1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma: a machine learning approach.The journal of pathology. Clinical research · 2023Article
- Case Report: Pancreatic metastasis of renal cell carcinoma 16 years after nephrectomy.Frontiers in oncology · 2023Article
- Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2022Review
- Review
- miRNA Pattern in Hypoxic Microenvironment of Kidney Cancer-Role of PTEN.Biomolecules · 2022Article
- Research Progress of PI3K/PTEN/AKT Signaling Pathway Associated with Renal Cell Carcinoma.Disease markers · 2022Review
- PTEN as a Therapeutic Target in Pulmonary Hypertension Secondary to Left-heart Failure: Effect of HO-3867 and Supplemental Oxygenation.Cell biochemistry and biophysics · 2021Review
- Article
- Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.Bioscience reports · 2020Article
- Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma.PeerJ · 2020Article
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.Clinical and experimental medicine · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phosphatase and tensin homolog (PTEN) gene is suggested to be a dormant tumor suppressor. However, the prognostic value of the loss of PTEN expression in renal cell carcinoma (RCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the association of PTEN expression with the clinicopathological presentations and outcomes of patients with RCC through immunohistochemistry staining analysis. We systematically searched for relevant studies in PubMed, Web of Science, and Embase until March 2016. Data regarding clinical stage, pathological type, Fuhrman grade, overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) was analyzed in the present study. In total, there were 12 studies with 2,368 patients included in this meta-analysis. The low PTEN expression in RCC was significantly associated with unfavorable DSS (HR = 1.568, 95% CI 1.015-2.242) in a random-effects model but not with OS (HR = 1.046, 95% CI 0.93-1.176) and PFS (HR = 1.244, 95% CI 0.907-1.704). Other results indicated that PTEN expression was not correlated with clinical stage, pathological type, and Fuhrman grade. This meta-analysis suggests that PTEN expression is of limited value in predicting the prognosis of patients with RCC for OS and PFS via immunohistochemistry staining analysis; and that for DSS, low PTEN expression is significantly associated with an unfavorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.